Valsartan

"Valsartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.

Descriptor ID	D000068756
MeSH Number(s)	D03.383.129.617.850 D12.125.070.950.550 D12.125.142.930.500
Concept/Terms	Valsartan Valsartan N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine Diovan Diovan Kalpress Kalpress Tareg Tareg Nisis Nisis Provas Provas Vals Vals CGP 48933 CGP 48933 48933, CGP Miten Miten

Below are MeSH descriptors whose meaning is more general than "Valsartan".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Tetrazoles [D03.383.129.617]
Valsartan [D03.383.129.617.850]
Amino Acids, Peptides, and Proteins [D12]
Amino Acids [D12.125]
Amino Acids, Branched-Chain [D12.125.070]
Valine [D12.125.070.950]
Valsartan [D12.125.070.950.550]
Amino Acids, Essential [D12.125.142]
Valine [D12.125.142.930]
Valsartan [D12.125.142.930.500]

Below are MeSH descriptors whose meaning is related to "Valsartan".

Below are MeSH descriptors whose meaning is more specific than "Valsartan".

Valsartan
Amlodipine, Valsartan Drug Combination

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Valsartan" by people in this website by year, and whether "Valsartan" was a major or minor topic of these publications.

Bar chart showing 92 publications over 21 distinct years, with a maximum of 12 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	2	2
1998	0	1	1
1999	0	1	1
2001	0	1	1
2003	0	1	1
2004	0	2	2
2006	0	1	1
2007	0	1	1
2010	0	2	2
2011	0	1	1
2012	0	2	2
2013	0	2	2
2014	0	6	6
2015	0	7	7
2016	3	9	12
2017	2	5	7
2018	1	9	10
2019	2	7	9
2020	4	5	9
2021	3	7	10
2022	0	5	5

Below are the most recent publications written about "Valsartan" by people in Profiles.

Wijkman MO, Claggett B, Vaduganathan M, Cunningham JW, Rørth R, Jackson A, Packer M, Zile M, Rouleau J, Swedberg K, Lefkowitz M, Shah SJ, Pfeffer MA, McMurray JJV, Solomon SD. Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol. 2022 06 18; 21(1):110.

View in: PubMed
Cikes M, Planinc I, Claggett B, Cunningham J, Milicic D, Sweitzer N, Senni M, Gori M, Linssen G, Shah SJ, Packer M, Pfeffer M, Zile MR, Anand I, Chiang LM, Lam CSP, Redfield M, Desai AS, McMurray JJV, Solomon SD. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2022 05; 10(5):336-346.

View in: PubMed
Pabón MA, Cunningham JW, Claggett BL, Packer M, Zile M, Pfeffer MA, Lefkowitz M, Shi V, Rizkala A, McMurray JJV, Solomon SD, Vaduganathan M. Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF. Eur J Heart Fail. 2022 04; 24(4):672-677.

View in: PubMed
Curtain JP, Jackson AM, Shen L, Jhund PS, Docherty KF, Petrie MC, Castagno D, Desai AS, Rohde LE, Lefkowitz MP, Rouleau JL, Zile MR, Solomon SD, Swedberg K, Packer M, McMurray JJV. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. Eur J Heart Fail. 2022 03; 24(3):551-561.

View in: PubMed
Mc Causland FR, Lefkowitz MP, Claggett B, Packer M, Senni M, Gori M, Jhund PS, McGrath MM, Rouleau JL, Shi V, Swedberg K, Vaduganathan M, Zannad F, Pfeffer MA, Zile M, McMurray JJV, Solomon SD. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022 Sep; 24(9):1591-1598.

View in: PubMed
Jackson AM, Jhund PS, Anand IS, Düngen HD, Lam CSP, Lefkowitz MP, Linssen G, Lund LH, Maggioni AP, Pfeffer MA, Rouleau JL, Saraiva JFK, Senni M, Vardeny O, Wijkman MO, Yilmaz MB, Saito Y, Zile MR, Solomon SD, McMurray JJV. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021 09 21; 42(36):3741-3752.

View in: PubMed
Gori M, Senni M, Claggett B, Liu J, Maggioni AP, Zile M, Prescott MF, Van Veldhuisen DJ, Zannad F, Pieske B, Lam CSP, Rouleau J, Jhund P, Packer M, Pfeffer MA, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. JACC Heart Fail. 2021 09; 9(9):627-635.

View in: PubMed
Suzuki K, Claggett B, Minamisawa M, Packer M, Zile MR, Pfeffer MA, Chiang LM, Lefkowitz M, McMurray JJV, Solomon SD, Desai AS. Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial. Eur J Heart Fail. 2021 12; 23(12):2085-2090.

View in: PubMed
Bhatt AS, Vaduganathan M, Claggett BL, Liu J, Packer M, Desai AS, Lefkowitz MP, Rouleau JL, Shi VC, Zile MR, Swedberg K, Vardeny O, McMurray JJV, Solomon SD. Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021 09; 23(9):1518-1524.

View in: PubMed
Bhatt AS, Claggett BL, Packer M, Lefkowitz MP, Zile MR, McMurray JJV, Solomon SD, Vaduganathan M. Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. J Card Fail. 2021 09; 27(9):1027-1030.

View in: PubMed

People

Explore

Similar Concepts

Top Journals